* Taysha Gene Therapies Inc reported a quarterly adjusted loss of 10 cents per share for the quarter ended September 30, higher than the same quarter last year, when the company reported EPS of -13 cents. The mean expectation of eleven analysts for the quarter was for a loss of 9 cents per share. Wall Street expected results to range from -11 cents to -8 cents per share.
* Revenue fell 62.3% to $1.79 million from a year ago; analysts expected $1.65 million.
* Taysha Gene Therapies Inc's reported EPS for the quarter was a loss of 10 cents.
* The company reported a quarterly loss of $25.52 million.
* Taysha Gene Therapies Inc shares had risen by 18.9% this quarter and gained 35.0% so far this year.
FORECAST CHANGES
* The mean earnings estimate of analysts had risen by about 1.7% in the last three months.
* In the last 30 days, there have been no earnings estimate revisions by analysts covering the company.
RECOMMENDATIONS
* The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 11 "strong buy" or "buy," no "hold" and no "sell" or "strong sell."
* The average consensus recommendation for the biotechnology & medical research peer group is also "buy"
Wall Street's median 12-month price target for Taysha Gene Therapies Inc is $7.00 This summary was machine generated from LSEG data November 14 at 04:04 a.m. UTC. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com) QUARTER ENDING ESTIMATE ACTUAL BEAT, MET,
MISSED
Sep. 30 2024 -0.09 -0.10 Missed
Jun. 30 2024 -0.16 -0.09 Beat
Mar. 31 2024 -0.11 -0.10 Beat
Dec. 31 2023 -0.11 0.92 Beat
Comments